MDACC Study No:2011-0184 ( NCT No: NCT01392170)
Title:Phase II Study of Pegylated Ifn-2a (Pegasys) in Patients with Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy with Tyrosine Kinase Inhibitors
Principal Investigator:Alfonso Quintas-Cardama
Treatment Agent:Peginterferon Alpha-2a
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if adding pegylated
interferon-alfa 2a (Pegasys) to the TKI that you are already receiving can help
to control CML. The safety of this treatment combination will also be studied.

Pegasys is a form of the drug interferon. It is designed to help the body’s
immune system to fight infections. It may also affect the body’s response to

A TKI (imatinib mesylate, nilotinib, or dasatinib) is designed to bind to and
shut off a protein in tumor cells called Bcr-Abl. Shutting Bcr-Abl off may
prevent CML cells from growing, and may cause them to die.

You are already receiving a TKI. This consent form will describe the
administration of Pegasys, any tests and procedures that need to be performed
while you are receiving Pegasys, and any risks/benefits there may be from
receiving Pegasys.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Peginterferon Alpha-2a
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Alfonso Quintas-Cardama
For Clinical Trial Enrollment:713-745-4009
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults